1. To assess the acute and long-term bimodal efficacy of iloperidone (IL), as an adjunct to
ongoing treatment with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any
combination of the three thereof, in a group of patients with an index episode of a
mixed state in BD.
2. To assess background, baseline features, and behavioral components which characterize
treatment response/non-response in the acute and long term management of MS
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio